drugset / Trial / NCT01399008
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol alone.
Timeline
- Start
- 2011-06
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arhalofenate | Unknown | 400 mg | Oral |
| Subject | Arhalofenate | Unknown | 600 mg | Oral |
| Background | Allopurinol | Small molecule | 300 mg | Oral |
| Background | Colchicine | Small molecule | 0.6 mg | — |